Paul Jordan

Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease

Iain C. Macdougall, Richard A. Robson, Sylvie Opatrná et al. · Clinical Journal of the American Society of Nephrology · 2006 · 188 citations

Hemodialysis, Urology, Renal Function +14

Urinary Tract Infection Caused by Staphylococcus saprophyticus

Paul Jordan, A Iravani, G. A. Richard et al. · The Journal of Infectious Diseases · 1980 · 186 citations

Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial

Norbert Stefan, Markus Ramsauer, Paul Jordan et al. · The Lancet Diabetes & Endocrinology · 2014 · 113 citations

Metabolic Syndrome, Metabolic Associated Steatohepatitis, Hepatology +11

Gastrointestinal lymphatics in health and disease

J. Steven Alexander, Vijay C. Ganta, Paul Jordan et al. · Pathophysiology · 2009 · 111 citations · Full text

A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a <i>SMN2</i> splicing modifier

Stefan Sturm, Andreas Guenther, Birgit Jaber et al. · British Journal of Clinical Pharmacology · 2018 · 98 citations · Full text